A detailed history of First Horizon Advisors, Inc. transactions in Harmony Biosciences Holdings, Inc. stock. As of the latest transaction made, First Horizon Advisors, Inc. holds 34 shares of HRMY stock, worth $1,186. This represents 0.0% of its overall portfolio holdings.

Number of Shares
34
Holding current value
$1,186
% of portfolio
0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 19, 2024

BUY
$28.81 - $33.01 $979 - $1,122
34 New
34 $1,000
Q3 2023

Oct 27, 2023

SELL
$31.89 - $39.03 $19,421 - $23,769
-609 Closed
0 $0
Q2 2023

Aug 03, 2023

SELL
$30.5 - $37.4 $3,812 - $4,675
-125 Reduced 17.03%
609 $21,000
Q1 2023

May 15, 2023

BUY
$30.8 - $53.92 $7,977 - $13,965
259 Added 54.53%
734 $23,000
Q4 2022

Feb 10, 2023

BUY
$45.4 - $60.91 $21,565 - $28,932
475 New
475 $26,000

Others Institutions Holding HRMY

About Harmony Biosciences Holdings, Inc.


  • Ticker HRMY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,161,400
  • Market Cap $2.07B
  • Description
  • Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony ...
More about HRMY
Track This Portfolio

Track First Horizon Advisors, Inc. Portfolio

Follow First Horizon Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Horizon Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on First Horizon Advisors, Inc. with notifications on news.